Modality
Bispecific Ab
MOA
JAK1/2i
Target
PRMT5
Pathway
Notch
ThymomaGastric Ca
Development Pipeline
Preclinical
Apr 2022
→ Nov 2029
PreclinicalCurrent
NCT04418365
840 pts·Thymoma
2022-04→2029-11·Not yet recruiting
840 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-11-043.6y awayInterim· Thymoma
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Preclinical
Not yet…
Catalysts
Interim
2029-11-04 · 3.6y away
Thymoma
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04418365 | Preclinical | Thymoma | Not yet recr... | 840 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin |